| Primary |
| Mucosal Inflammation |
63.2% |
| Stomatitis |
16.0% |
| Peripheral Blood Stem Cell Apheresis |
9.4% |
| Drug Use For Unknown Indication |
4.7% |
| Radiation Dysphagia |
3.8% |
| Hiv Infection |
1.9% |
| Neutropenia |
0.9% |
|
| Tongue Disorder |
10.3% |
| Performance Status Decreased |
8.8% |
| Hypersensitivity |
7.4% |
| Mechanical Ileus |
7.4% |
| Stomatitis |
7.4% |
| Weight Decreased |
7.4% |
| Skin Hyperpigmentation |
5.9% |
| Vomiting |
5.9% |
| Gingival Hyperplasia |
4.4% |
| Tachycardia |
4.4% |
| White Blood Cell Count Increased |
4.4% |
| Anaemia |
2.9% |
| Capillary Leak Syndrome |
2.9% |
| Central Line Infection |
2.9% |
| Neutropenia |
2.9% |
| Pancreatitis Acute |
2.9% |
| Portal Vein Thrombosis |
2.9% |
| Psychotic Disorder Due To A General Medical Condition |
2.9% |
| Pulmonary Toxicity |
2.9% |
| Pyrexia |
2.9% |
|
| Secondary |
| Acute Myeloid Leukaemia |
26.5% |
| Drug Use For Unknown Indication |
26.5% |
| Product Used For Unknown Indication |
9.5% |
| Mucosal Inflammation |
7.5% |
| Transplant |
6.8% |
| Prophylaxis |
4.8% |
| Nausea |
2.7% |
| Off Label Use |
2.7% |
| Testicular Germ Cell Cancer |
2.7% |
| Multiple Myeloma |
2.0% |
| Myeloid Leukaemia |
2.0% |
| Peripheral Blood Stem Cell Apheresis |
2.0% |
| Autoimmune Disorder |
1.4% |
| B-cell Lymphoma |
1.4% |
| Lupus Nephritis |
1.4% |
|
| Intestinal Obstruction |
10.3% |
| Lymphocytosis |
10.3% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
10.3% |
| Neutropenic Colitis |
6.9% |
| Oedema Mucosal |
6.9% |
| Pancytopenia |
6.9% |
| Rash |
6.9% |
| Toxic Epidermal Necrolysis |
6.9% |
| Axonal Neuropathy |
3.4% |
| Bone Marrow Failure |
3.4% |
| Candidiasis |
3.4% |
| Cardiotoxicity |
3.4% |
| Mucosal Inflammation |
3.4% |
| Nephritis Interstitial |
3.4% |
| Thrombocytopenia |
3.4% |
| Unevaluable Event |
3.4% |
| Vomiting |
3.4% |
| White Blood Cell Count Increased |
3.4% |
|
| Concomitant |
| Burkitt's Lymphoma |
19.4% |
| B Precursor Type Acute Leukaemia |
18.9% |
| Stomatitis |
17.6% |
| B-cell Lymphoma |
8.8% |
| Analgesic Therapy |
4.4% |
| Antifungal Prophylaxis |
4.4% |
| Infection |
4.4% |
| Neutropenia |
4.4% |
| Bone Marrow Conditioning Regimen |
2.6% |
| Bone Sarcoma |
2.2% |
| Malignant Lymphoid Neoplasm |
2.2% |
| Grand Mal Convulsion |
1.8% |
| Prophylaxis |
1.8% |
| Hyperkalaemia |
1.3% |
| Nephropathy Toxic |
1.3% |
| Acute Myeloid Leukaemia |
0.9% |
| Bronchopulmonary Aspergillosis |
0.9% |
| Pleural Effusion |
0.9% |
| Product Used For Unknown Indication |
0.9% |
| Prophylaxis Against Graft Versus Host Disease |
0.9% |
|
| Stomatitis |
35.7% |
| Venous Stent Insertion |
28.6% |
| Renal Failure Acute |
7.1% |
| Acute Graft Versus Host Disease In Skin |
3.6% |
| Hepatocellular Damage |
3.6% |
| Musculoskeletal Chest Pain |
3.6% |
| Pulmonary Embolism |
3.6% |
| Pyrexia |
3.6% |
| Respiratory Distress |
3.6% |
| Sepsis |
3.6% |
| Stem Cell Transplant |
3.6% |
|
